Sweat glands are switched on by acetylcholine, a chemical messenger released by nerve endings. Sofpironium blocks the muscarinic receptor that acetylcholine acts on, so the signal never lands and the gland does not produce sweat.
That is the same mechanism as Qbrexza, as oral glycopyrrolate, and as oxybutynin. It is also, in a different way, what Botox does — Botox stops the nerve releasing acetylcholine in the first place, rather than blocking the receptor.
The design idea behind sofpironium is what the manufacturer calls a "soft" drug: the molecule is built to be broken down into an inactive form once it enters the bloodstream. In principle that keeps the effect in the skin and reduces the whole-body anticholinergic effects. In practice, dry mouth, blurred vision, and dilated pupils still show up in the trials, so treat this as a design improvement rather than a solved problem.
Pregnancy and breastfeeding data are limited. Discuss it rather than assuming either way.
No blood tests are required, and there is no scheduled monitoring on Sofdra. What matters instead is symptom awareness.
Be alert to urinary retention, particularly if you are a man over 50 or have any history of prostate trouble. Difficulty starting, a weak stream, or incomplete emptying should be reported rather than tolerated.
Watch for the anticholinergic load adding up if you take other drugs in the same family — bladder medications, sedating antihistamines, tricyclics, some Parkinson's drugs. There is no test for this; it comes down to an honest medication list.
Keep an eye on how you handle heat during the first hot spell after starting. Not sweating at all when you should be is a signal to stop using it during those conditions.
Any eye symptoms — pain, redness, persistent blurring, a pupil that stays dilated — should be assessed rather than waited out.
Some reduction in sweating usually shows up within the first couple of weeks, and the trials assessed the result at six weeks. Give it a full six weeks of consistent nightly use before deciding whether it is worth continuing.
It reduces sweating; it does not stop it. Expect an improvement you can live with rather than dry underarms.
Sweating returns to baseline within days. There is no rebound and no withdrawal.
Sofdra is a maintenance treatment, not a course — the effect lasts only as long as you keep applying it. That is the main practical difference between it and Botox, which lasts months per treatment, or miraDry, which is intended to be permanent. It is worth weighing that against the cost, because a nightly gel indefinitely adds up.